Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to develop, evaluate, and optimize an interactive website (the SMART portal). The SMART portal will use IBD-specific and general assessments and interventions to reduce the burden of common barriers to treatment adherence and enhance self-management skills. This study aims to build and revise the SMART portal according to feedback and testing from participants.
The study consists of three phases for development and evaluation of the SMART portal. Phase 1 is the development of online assessments and intervention components. There will be no participant interaction with the portal during Phase 1. Phase 2 will consist of one, individual interview with patients, caregivers, and clinicians/nurses to interact with a portal prototype and provide feedback. Phase 3 will contain an open trial for patients and caregivers with baseline, 2-6 months interacting with the portal and progressing through applicable intervention components, and post-treatment. Patient test data will also be loaded into the portal during Phase 3 for clinicians/nurses to interact with for 2-6 months. Feedback from all users will be collected at post-treatment for optimization of the portal.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Clinicians/Nurses | Clinicians and nurses who treat patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization. | ||
| Patients | Patients age 11-18 years diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization. | ||
| Caregivers | Caregivers of patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Medication adherence | Medication adherence will be measured by pill count data provided by patients or caregivers at baseline and post-treatment during Phase 3. Phase 3 will start approximately in October 2014 and continue through March 2015. | Phase 3 - Approximately 2-6 months, depending upon progression through portal components |
| Measure | Description | Time Frame |
|---|---|---|
| Disease severity | Disease severity will be measured at baseline, post-treatment, and periodically throughout the intervention as the patient logs in to view intervention materials during Phase 3. The portal will prompt the patient to complete disease severity questions throughout the intervention, but it will be dependent upon the patient actually logging into the system. Therefore, exact time points during treatment are unknown. The Pediatric Ulcerative Colitis Activity Index (PUCAI) will be used to measure disease severity for patients diagnosed with ulcerative colitis and indeterminate colitis, and the Partial Harvey Bradshaw (PHBI) will be used for patients diagnosed with Crohn's disease. Phase 3 will start approximately in October 2014 and continue through March 2015. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients, caregivers, clinicians, and nurses will be recruited from the IBD clinic at Cincinnati Children's Hospital Medical Center.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lee Denson, M.D. | Children's Hospital Medical Center, Cincinnati | Study Chair |
| James Peugh, Ph.D. | Children's Hospital Medical Center, Cincinnati | Study Chair |
| Korey Hood, Ph.D. | University of California, San Francisco | Study Chair |
| Lee Ritterband, Ph.D. | BeHealth Solutions, LLC. | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | United States | ||
| BeHealth Solutions, LLC |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36123761 | Derived | Hommel KA, Ramsey RR, Gray WN, Denson LA. Digital Therapeutic Self-Management Intervention in Adolescents With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023 Jan 1;76(1):38-42. doi: 10.1097/MPG.0000000000003623. Epub 2022 Sep 20. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| D003093 | Colitis, Ulcerative |
| D015212 | Inflammatory Bowel Diseases |
| ID | Term |
|---|---|
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Phase 3 - Approximately 2-6 months, depending upon progression through portal components |
| Health-related quality of life | The IMPACT-III will be used during baseline and post-treatment in Phase 3 to measure quality of life in patients. Phase 3 will start approximately in October 2014 and continue through March 2015. | Phase 3 - Approximately 2-6 months, depending upon progression through portal components |
| Charlottesville |
| Virginia |
| 22901 |
| United States |
| D003092 | Colitis |
| D003108 | Colonic Diseases |